The occurrence of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation for leukemia is thought to decrease the probability of recurrence. To study this effect (called adoptive immunotherapy) we modified the prophylaxis of GVHD in patients with advanced hematologic neoplasms (mostly leukemia) who received bone marrow transplants. Patients under 30 years of age were randomly assigned to one of three regimens of post-transplantation immunosuppression: Group I (n = 44) received a standard course of methotrexate for 102 days after transplantation, Group II (n = 40) received an abbreviated (11-day) course of methotrexate, and Group III (n = 25) received the standard course of methotrexate plus viable buffy-coat cells from the marrow donors. All 109 patients received cyclophosphamide (60 mg per kilogram of body weight on each of two days), total-body irradiation (2.25 Gy daily for seven days), and unmodified marrow from HLA-identical sibling donors. The frequency of GVHD of Grades II through IV was 25 percent in Group I, 59 percent in Group II, and 82 percent in Group III (P = 0.0001). The incidence of chronic GVHD, however, did not differ significantly among the groups (33, 51, and 44 percent, respectively), nor did the five-year probability of recurrence of disease (38, 45, and 33 percent, respectively). However, mortality from causes other than cancer was 34 percent in Group I, 45 percent in Group II, and 64 percent in Group III (I vs. III, P = 0.024); the deaths were due primarily to infections complicating the course of GVHD. With a median follow-up of 5.1 years (range, 3.9 to 7.4), disease-free survival was 41 percent in Group I, 30 percent in Group II, and 24 percent in Group III (the differences were not statistically significant). We conclude that abbreviating methotrexate prophylaxis or infusing donor buffy-coat cells increased the incidence of acute GVHD and related mortality without altering the incidence of chronic GVHD or the recurrence of malignant disease.
Source Information
Fred Hutchinson Cancer Research Center, Seattle, WA.
This article has been cited by other articles:
Antin, J. H.
(2007). Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. ASH Education Book
2007: 47-54
[Abstract][Full Text]
Rezvani, K., Brenchley, J. M., Price, D. A., Kilical, Y., Gostick, E., Sewell, A. K., Li, J., Mielke, S., Douek, D. C., Barrett, A. J.
(2005). T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization. Clin. Cancer Res.
11: 8799-8807
[Abstract][Full Text]
Kolb, H.-J., Schmid, C., Barrett, A. J., Schendel, D. J.
(2004). Graft-versus-leukemia reactions in allogeneic chimeras. Blood
103: 767-776
[Abstract][Full Text]
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., Jensen, M. C.
(2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood
101: 1637-1644
[Abstract][Full Text]
Ballen, K. K., Becker, P. S., Emmons, R. V. B., Fitzgerald, T. J., Hsieh, C. C., Liu, Q., Heyes, C., Clark, Y., Levy, W., Lambert, J. F., Chiafari, F., Szymanski, I., Rososhansky, S., Popovsky, M. A., Stewart, F. M., Quesenberry, P. J.
(2002). Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood
100: 442-450
[Abstract][Full Text]
Kiss, T.L., Abdolell, M., Jamal, N., Minden, M.D., Lipton, J.H., Messner, H.A.
(2002). Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation. JCO
20: 2334-2343
[Abstract][Full Text]
Wang, J., Shaw, J. L., Mullen, C. A.
(2002). Down-Regulation of Antihost Alloreactivity after Bone Marrow Transplant Permits Relapse of Hematological Malignancy. Cancer Res.
62: 208-212
[Abstract][Full Text]
Morton, J., Hutchins, C., Durrant, S.
(2001). Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood
98: 3186-3191
[Abstract][Full Text]
Luznik, L., Jalla, S., Engstrom, L. W., Iannone, R., Fuchs, E. J.
(2001). Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood
98: 3456-3464
[Abstract][Full Text]
Appelbaum, F. R., Rowe, J. M., Radich, J., Dick, J. E.
(2001). Acute Myeloid Leukemia. ASH Education Book
2001: 62-86
[Abstract][Full Text]
Storb, R. F., Champlin, R., Riddell, S. R., Murata, M., Bryant, S., Warren, E. H.
(2001). Non-Myeloablative Transplants for Malignant Disease. ASH Education Book
2001: 375-391
[Abstract][Full Text]
McCarthy, N. J., Bishop, M. R.
(2000). Nonmyeloablative Allogeneic Stem Cell Transplantation: Early Promise and Limitations. The Oncologist
5: 487-496
[Abstract][Full Text]
Blazar, B. R., Lees, C. J., Martin, P. J., Noelle, R. J., Kwon, B., Murphy, W., Taylor, P. A.
(2000). Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions. J. Immunol.
165: 4901-4909
[Abstract][Full Text]
Bonnet, D., Warren, E. H., Greenberg, P. D., Dick, J. E., Riddell, S. R.
(1999). CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. USA
96: 8639-8644
[Abstract][Full Text]
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., Emerson, S. G.
(1999). Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells. Science
285: 412-415
[Abstract][Full Text]
Adkins, D., Brown, R., Goodnough, L., Khoury, H., DiPersio, J., Khouri, I., Champlin, R.
(1999). Purine Analog Regimens for Allogeneic Transplant?. JCO
17: 1958-1960
[Full Text]
Anderson, L. D. Jr., Petropoulos, D., Everse, L. A., Mullen, C. A.
(1999). Enhancement of Graft-Versus-Tumor Activity and Graft-Versus-Host Disease by Pretransplant Immunization of Allogeneic Bone Marrow Donors with a Recipient-derived Tumor Cell Vaccine. Cancer Res.
59: 1525-1530
[Abstract][Full Text]
Sehn, L. H., Alyea, E. P., Weller, E., Canning, C., Lee, S., Ritz, J., Antin, J. H., Soiffer, R. J.
(1999). Comparative Outcomes of T-Cell–Depleted and Non–T-Cell–Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. JCO
17: 561-561
[Abstract][Full Text]
Alyea, E. P., Soiffer, R. J., Canning, C., Neuberg, D., Schlossman, R., Pickett, C., Collins, H., Wang, Y., Anderson, K. C., Ritz, J.
(1998). Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. Blood
91: 3671-3680
[Abstract][Full Text]
Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Horton, C., Mehta, J.
(1998). Identification of Patients Who May Benefit From Prophylactic Immunotherapy After Bone Marrow Transplantation for Acute Myeloid Leukemia on the Basis of Lymphocyte Recovery Early After Transplantation. Blood
91: 3481-3486
[Abstract][Full Text]
Sierra, J., Storer, B., Hansen, J. A., Bjerke, J. W., Martin, P. J., Petersdorf, E. W., Appelbaum, F. R., Bryant, E., Chauncey, T. R., Sale, G., Sanders, J. E., Storb, R., Sullivan, K. M., Anasetti, C.
(1997). Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. Blood
89: 4226-4235
[Abstract][Full Text]
Deeg, H. J., Lin, D., Leisenring, W., Boeckh, M., Anasetti, C., Appelbaum, F. R., Chauncey, T. R., Doney, K., Flowers, M., Martin, P., Nash, R., Schoch, G., Sullivan, K. M., Witherspoon, R. P., Storb, R.
(1997). Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. Blood
89: 3880-3887
[Abstract][Full Text]
Soiffer, R. J., Fairclough, D., Robertson, M., Alyea, E., Anderson, K., Freedman, A., Bartlett-Pandite, L., Fisher, D., Schlossman, R. L., Stone, R., Murray, C., Freeman, A., Marcus, K., Mauch, P., Nadler, L., Ritz, J.
(1997). CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission. Blood
89: 3039-3047
[Abstract][Full Text]
Munshi, N.C., Govindarajan, R., Drake, R., Ding, L.M., Iyer, R., Saylors, R., Kornbluth, J., Marcus, S., Chiang, Y., Ennist, D., Kwak, L., Reynolds, C., Tricot, G., Barlogie, B.
(1997). Thymidine Kinase (TK) Gene-Transduced Human Lymphocytes Can Be Highly Purified, Remain Fully Functional, and Are Killed Efficiently With Ganciclovir. Blood
89: 1334-1340
[Abstract][Full Text]
Armitage, J. O.
(1994). Bone Marrow Transplantation. NEJM
330: 827-838
[Full Text]
Porter, D. L., Roth, M. S., McGarigle, C., Ferrara, J., Antin, J. H.
(1994). Induction of Graft-versus-Host Disease as Immunotherapy for Relapsed Chronic Myeloid Leukemia. NEJM
330: 100-106
[Abstract][Full Text]
Previous
